Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
82.00
+3.00 (3.80%)
Jul 10, 2026, 3:30 PM JST
Market Cap6.34B -60.8%
Revenue (ttm)n/a
Net Income-1.44B
EPS-20.64
Shares Out 77.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume285,800
Open80.00
Previous Close79.00
Day's Range79.00 - 83.00
52-Week Range66.00 - 220.00
Beta3.14
Analystsn/a
Price Targetn/a
Earnings DateJul 15, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements